Workflow
皓元医药: 上海皓元医药股份有限公司关于2022年限制性股票激励计划首次授予部分第三个归属期以及预留部分第二个归属期归属结果暨股份上市公告

Core Viewpoint - The announcement details the results of the third vesting period of the 2022 Restricted Stock Incentive Plan and the second vesting period of the reserved portion, with a total of 648,570 shares set to be listed for trading on July 8, 2025 [1][15]. Summary by Sections Important Content Highlights - The total number of shares for this stock listing is 648,570, which is part of the equity incentive shares [1]. - The vesting registration for the third vesting period and the reserved portion's second vesting period was completed on June 30, 2025 [1]. Decision-Making Process and Disclosure - The board of directors approved the incentive plan on January 26, 2022, with independent directors and legal advisors providing their consent [2][5]. - The proposed list of incentive recipients was publicly disclosed from January 27 to February 5, 2022, with no objections received [3]. - The shareholders approved the incentive plan at a meeting on February 15, 2022 [4]. Vesting Details - For the first grant portion, 84 individuals received a total of 480,868 shares, representing 39.92% of the total granted shares [10]. - The reserved portion had 20 individuals eligible for 167,702 shares, with 50% of the reserved shares vesting [11][13]. Stock Listing and Capital Changes - The total share capital increased from 210,961,003 to 211,609,573 shares due to this vesting [14]. - The company received a total of RMB 25,553,658.00 from the incentive recipients, contributing to an increase in share capital and capital reserves [15]. Financial Impact - The basic earnings per share for Q1 2025 will be diluted due to the increase in total shares, with the net profit for the period reported at RMB 62,384,400.02 [15].